Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer

Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT07419880 by Fudan University, with a registry enrolment figure of 46 participants, started 2026-01-30 and due to reach its primary completion in 2027-01-30. Interventions recorded: Cromolyn, TQB2102, and Panpulimab. Conditions listed: Triple -Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Diagnosis: Histologically confirmed invasive triple-negative breast cancer (defined as: ER-negative by IHC with \<1% positive tumor cells; PR-negative with \<1% positive tumor cells; HER2 0-1+ or HER2 2+ with confirmed negative FISH/CISH without amplification)". Sites: China. No results are recorded here; the registry entry is the source.